Biocon Pharma Ltd.

Let me gather more detail on Biocon Pharma's operations and the parent company's size.

Company overview. Biocon Pharma Limited is an Indian generics manufacturer and a wholly-owned subsidiary of Biocon Limited, the Bengaluru-based biopharmaceutical group founded in 1978 by Kiran Mazumdar-Shaw. Biocon Limited is publicly listed on the BSE (532523) and NSE (BIOCON); its registered office is at Biocon Campus, Hosur Road, Electronic City, Bengaluru. Biocon Pharma was established in FY2016 to house the group's Generic Formulations business. Parent-scale figures (FY2025): consolidated revenue of roughly ₹15,262 crore (~US$1.9B), ~16,000 employees, and market capitalisation in the ₹47,000–70,000 crore range depending on measurement date. Biocon Pharma itself is not separately listed; it wholly owns Biocon Pharma Inc. (US), Biocon Pharma UK Limited, Biocon Pharma Ireland Limited, and Biocon Pharma Malta Limited.

Products / operations. Biocon Pharma is an operating generics business, not a shell. It manufactures and sells finished-dosage generic formulations — oral solids and parenterals, including potent and non-potent compounds — across cardiology, metabolics/diabetes, oncology, and immunology/autoimmune areas, and it forward-integrates the parent's active pharmaceutical ingredients (statins, immunosuppressants, peptides, oncology APIs). It operates a GMP-compliant formulations facility at Biocon Park, Bengaluru, which has received UK MHRA GMP certification.

Patent-litigation posture. A pure defendant. The tracked data show 1 case, 0 as plaintiff and 1 as defendant, which is the classic profile of an operating company defending its generic drug filings rather than an NPE asserting patents. The single venue is the District of New Jersey — a standard ANDA/Hatch-Waxman forum, not a plaintiff-friendly NPE venue like the Eastern District of Texas.

Notable case. Celgene Corp. v. Biocon Pharma Ltd. et al. (D.N.J., 2:21-cv-11261), filed 14 May 2021. Celgene (now a Bristol Myers Squibb subsidiary) sued Biocon Pharma, Biocon Limited, and Biocon Pharma Inc. under 35 U.S.C. §271, alleging that Biocon's Abbreviated New Drug Application for generic REVLIMID (lenalidomide) capsules would infringe Celgene's patents. Biocon answered and counterclaimed for invalidity/non-infringement; the parties later entered a confidential settlement. No merits determinations are attributed here.